Ingavirin
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Ingavirin
- Molecular weight
- 225.25
- Structure (SMILES)
- O=C(O)CCCC(=O)NCCc1c[nH]cn1
- dicarbamin
- DICARBAMIN
- imidazolyl ethanamide pentandioic acid
- Imidazolyl ethanamide pentandioic acid
- Imidazolyl ethanamide pentandioic acid [WHO-DD]
- imidazolyl ethanamide pentandioic acid who dd
- ingamine
- Ingamine
- ingavirin
- Ingavirin
- Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)
- Ingavirin®
- myelo 001
- Myelo-001
- myelo001
- Myelo001
- vitaglutam
- VITAGLUTAM
- CAS registry numbers
- 219694-63-0
- ChEMBL ID
- CHEMBL4297291
- InChIKey
- KZIMLUFVKJLCCH-UHFFFAOYSA-N
- PubChem compound IDs
- 9942657
- FDA ingredient codes (UNII)
- 3CM03MUJ69
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -vir-
- Condition identifier
- EFO_0007328
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- Event
- musculoskeletal chest pain
- Reports
- 1
- Reporting signal score
- 5.70317
- Event
- poisoning
- Reports
- 1
- Reporting signal score
- 6.29072
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 3
- Polar surface area
- 95.08
- Calculated partition coefficient (ALogP)
- 0.32
- Calculated partition coefficient (XLogP)
- -0.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 16
- Molecular formula
- C10H15N3O3
- Monoisotopic mass
- 225.11134135
- Natural product
- Yes
- Antiviral Agents
Related records
Trials (11)
- Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
- Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections
- Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
- Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
- Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.
- Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.
- Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
- Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
In development for (1)
- COVID-19 Phase 3